VEGFA and macular retinal edema: In comparison to initiating anti-VEGF due to DMO, there was 53% (HR 0.46; 95% CI 0.39–0.53; P < 0.001) and 47% (HR 0.51; 95% CI 0.43–0.62; P < 0.001) less chance of experiencing an unideal clinical outcome with macular oedema secondary to BRVO and CRVO, respectively (Table 3 and Supplementary Table 2).